• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Pliant Therapeutics Inc.

    11/12/24 11:53:39 AM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PLRX alert in real time by email
    SC 13G/A 1 plrxa1_111224.htm LAURION CAPITAL MANAGEMENT LP plrxa1_111224.htm
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
    Pliant Therapeutics, Inc.
    (Name of Issuer)
    Common Stock, par value $0.0001 per share
    (Title of Class of Securities)
    729139105
    (CUSIP Number)
    September 30, 2024
    (Date of Event which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [X] Rule 13d-1(b)
    [   ] Rule 13d-1(c)
    [   ] Rule 13d-1(d)
    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see Instructions).
    CUSIP No.: 729139105
           
    1
    NAME OF REPORTING PERSON
    Laurion Capital Management LP
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    56-2504425
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    6
    SHARED VOTING POWER
    0
    7
    SOLE DISPOSITIVE POWER
    8
    SHARED DISPOSITIVE POWER
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    0
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    0.0%
    12
    TYPE OF REPORTING PERSON
    IA, PN
    CUSIP No.: 729139105
           
    1
    NAME OF REPORTING PERSON
    Benjamin Alexander Smith
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    6
    SHARED VOTING POWER
    0
    7
    SOLE DISPOSITIVE POWER
    8
    SHARED DISPOSITIVE POWER
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    0
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    0.0%
    12
    TYPE OF REPORTING PERSON
    IN
    CUSIP No.: 729139105
           
    1
    NAME OF REPORTING PERSON
    Janaka Sheehan Maduraperuma
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    United Kingdom
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    6
    SHARED VOTING POWER
    0
    7
    SOLE DISPOSITIVE POWER
    8
    SHARED DISPOSITIVE POWER
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    0
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    0.0%
    12
    TYPE OF REPORTING PERSON
    IN
    CUSIP No.: 729139105
    ITEM 1(a). NAME OF ISSUER:
    Pliant Therapeutics, Inc.
    ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
    331 Oyster Point Boulevard
    South San Francisco, CA 94080
    ITEM 2(a). NAME OF PERSON FILING:
    This statement is filed by:

    Laurion Capital Management LP ("Laurion Capital"), a Delaware limited partnership, and the investment adviser to certain funds and accounts (the "Laurion Funds"), with respect to the shares of Common Stock (as defined in Item 2(d) below) directly held by the Laurion Funds;

    Mr. Benjamin Alexander Smith ("Mr. Smith"), the co-managing member of Laurion Capital GP LLC, the general partner of Laurion Capital, with respect to the shares of Common Stock directly held by the Laurion Funds.

    Mr. Janaka Sheehan Maduraperuma ("Mr. Maduraperuma"), the co-managing member of Laurion Capital GP LLC, the general partner of Laurion Capital, with respect to the shares of Common Stock directly held by the Laurion Funds.

    The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."

    The filing of this statement should not be construed as an admission that any of the forgoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock reported herein.
    ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
    The address of the business office of each of the Reporting Persons is 360 Madison Avenue, Suite 1900, New York, NY 10017.
    ITEM 2(c). CITIZENSHIP:
    Laurion Capital is a Delaware limited partnership. Mr. Smith is a citizen of the United States. Mr. Maduraperuma is a citizen of the United Kingdom.
    ITEM 2(d). TITLE OF CLASS OF SECURITIES:
    Common Stock, par value $0.0001 per share (the "Common Stock")
    ITEM 2(e). CUSIP NUMBER:
    729139105
    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTION 240.13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS A:
    (a)
    [ ]
    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78c);
    (b)
    [ ]
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)
    [ ]
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)
    [ ]
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
    (e)
    [X]
    An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
    (f)
    [ ]
    An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
    (g)
    [X]
    A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
    (h)
    [ ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    [ ]
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)
    [ ]
    A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J);
    (k)
    [ ]
    Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d1(b)(1)(ii)(J), please specify the type of institution:
    ITEM 4. OWNERSHIP
    The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

    The percentages set forth herein are calculated based upon 60,853,623 shares of Common Stock outstanding as of November 1, 2024 as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, filed with the Securities and Exchange Commission on November 7, 2024.
    (a) Amount beneficially owned:
    (b) Percent of class:
    (c) Number of shares as to which the person has:
    (i) sole power to vote or to direct the vote:
    (ii) shared power to vote or to direct the vote:
    (iii) sole power to dispose or direct the disposition of:
    (iv) shared power to dispose or to direct the disposition of:
    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].
    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
    Not applicable.
    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
    Not applicable.
    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
    Not applicable.
    ITEM 9. NOTICE OF DISSOLUTION OF GROUP:
    Not applicable.
    ITEM 10. CERTIFICATION:
    Each of the Reporting Persons hereby makes the following certification:

    By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
    CUSIP No.: 729139105
    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    November 12 2024
    Laurion Capital Management LP
    By:
    /s/ Jason Riesel
    Name:
    Jason Riesel
    Title:
    General Counsel & CCO
    November 12 2024
    By:
    /s/Benjamin Alexander Smith
    Name:
    BENJAMIN ALEXANDER SMITH
    Title:
    November 12 2024
    By:
    /s/Janaka Sheehan Maduraperuma
    Name:
    JANAKA SHEEHAN MADURAPERUMA
    Title:
    Attention — Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).
    Get the next $PLRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PLRX

    DatePrice TargetRatingAnalyst
    3/4/2025Buy → Hold
    Needham
    3/4/2025Neutral
    Cantor Fitzgerald
    3/3/2025Buy → Hold
    Stifel
    3/3/2025Outperform → Market Perform
    Leerink Partners
    2/10/2025Overweight → Neutral
    Analyst
    2/10/2025$43.00 → $4.00Buy → Hold
    Canaccord Genuity
    2/10/2025Outperform → Perform
    Oppenheimer
    2/10/2025$40.00 → $4.00Buy → Neutral
    Citigroup
    More analyst ratings

    $PLRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Pliant Therapeutics Inc.

      SC 13G - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)

      11/14/24 9:00:58 PM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Pliant Therapeutics Inc.

      SC 13G/A - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)

      11/14/24 5:05:23 PM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Pliant Therapeutics Inc.

      SC 13G/A - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)

      11/14/24 4:47:50 PM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PLRX
    Financials

    Live finance-specific insights

    See more

    $PLRX
    SEC Filings

    See more
    • Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement

      SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced that its Board of Directors has unanimously adopted a limited duration stockholder rights agreement (the "Rights Agreement") to protect stockholder interests. The Board resolved to adopt the Rights Agreement in response to recent accumulations of the Company's common stock. The Rights Agreement is intended to reduce the likelihood that any entity, person or group is able to gain control of Pliant through open market accumulation without paying all stockholders an appropriate control premium or providing the Board sufficient opportunity to make informed judgments and take

      3/13/25 7:20:00 AM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

      Bexotegrast (PLN-74809) at 320 mg was well tolerated over 12 weeks of treatment with no drug-related severe or serious adverse events; No safety concerns identified across all dose cohorts Bexotegrast at 320 mg reduced liver fibrosis markers ELF and PRO-C3 and showed improvements in hepatocyte function and bile flow by contrast MRI imaging relative to placebo at Week 12 The 320 mg data continue to demonstrate antifibrotic effects of bexotegrast, consistent with previous findings Company to host webcast and conference call tomorrow, Monday, February 5 at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Feb. 04, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced

      2/4/24 3:29:07 PM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

      Bexotegrast (PLN-74809) was well tolerated over 12 weeks of treatment with few discontinuations and no drug-related severe or serious adverse events Bexotegrast reduced both the Enhanced Liver Fibrosis (ELF) score and collagen synthesis biomarker PRO-C3 levels relative to placebo at all doses with statistical significance at the 160 mg dose Bexotegrast-treated patients showed improved liver biochemistry and imaging parameters relative to placebo at Week 12 Company to host webcast and conference call today, Tuesday, September 26 at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), today announced positive data f

      9/26/23 7:30:00 AM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Pliant Therapeutics Inc.

      SCHEDULE 13G/A - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)

      5/15/25 4:39:50 PM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Pliant Therapeutics Inc.

      SCHEDULE 13G/A - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)

      5/14/25 10:45:26 AM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Pliant Therapeutics Inc.

      10-Q - PLIANT THERAPEUTICS, INC. (0001746473) (Filer)

      5/8/25 4:16:45 PM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PLRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference

      SOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced that the Company led oral and poster presentations of clinical and preclinical data this week as part of the American Thoracic Society (ATS) 2025 International Conference, held from May 16-21, 2025. Characterizing the Antifibrotic Activity of Bexotegrast on Distinct Fibroblast Populations in PCLS from Multiple ILD SubtypesIn a featured oral presentation, Johanna Schaub, Ph.D., Director of Translational Sciences at Pliant Therapeutics, discussed an evaluation of the antifibrotic activity of bexotegrast in fibrotic human precision-cut lung slices (PCLS) generated from non-id

      5/21/25 4:03:00 PM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

      Activities supporting the close out of BEACON-IPF continue; topline data expected in the second quarter of 2025 Recently announced strategic realignment of workforce and operations will extend cash runway to support execution of late-stage clinical trials SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported first quarter 2025 financial results. "During the first quarter and over recent weeks, our teams have been working diligently to close out the g

      5/8/25 4:05:00 PM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations

      -  Implementation of cost reduction initiatives to position Pliant for execution of late-stage clinical trials -  Pliant will reduce its current workforce by approximately 45% -  Closing activities for BEACON-IPF trial ongoing; topline data expected in the second quarter of 2025 SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced a strategic restructuring of its workforce and other cost saving actions to extend the cash runway to support execution of late-stage clinical trials. The restructuring aims to minimize costs and preserve cash reserves as the Company awaits topline data from the BEACON-IPF Phase 2b/3 trial of be

      5/1/25 4:05:00 PM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PLRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Pliant Therapeutics downgraded by Needham

      Needham downgraded Pliant Therapeutics from Buy to Hold

      3/4/25 8:19:24 AM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald resumed coverage on Pliant Therapeutics

      Cantor Fitzgerald resumed coverage of Pliant Therapeutics with a rating of Neutral

      3/4/25 7:42:23 AM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pliant Therapeutics downgraded by Stifel

      Stifel downgraded Pliant Therapeutics from Buy to Hold

      3/3/25 3:36:54 PM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PLRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results

      Discontinuation of BEACON-IPF following DSMB and outside expert panel recommendation SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported fourth quarter 2024 financial results. Fourth Quarter and Recent Highlights Bexotegrast Highlights BEACON-IPF discontinued following recommendation from expanded data safety monitoring board (DSMB). Following a prespecified data review and recommendation by the trial's independent DSMB, as well as a secondary r

      3/3/25 4:05:00 PM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pliant Therapeutics Appoints Delphine Imbert, Ph.D. as Chief Technical Officer

      Dr. Imbert brings 25 years of strategic clinical to commercial-stage manufacturing and drug development experience SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the appointment of Delphine Imbert, Ph.D. as Chief Technical Officer. Dr. Imbert brings 25 years of product development, process optimization and manufacturing experience across multiple drug modalities, including small molecules. In this role, Dr. Imbert will lead chemistry, manufacturing and control (CMC)-related acti

      1/22/25 8:00:00 AM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

      BEACON-IPF Phase 2b trial on track for full enrollment in the first quarter of 2025 with data anticipated in mid-2026 SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a late-stage clinical biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported third quarter 2024 financial results. "A highlight to this quarter's progress was the continued strong execution of our BEACON-IPF Phase 2b/3 trial which is enrolling well and on track to complete enrollment in the first quarter of 2025," said Bernard Coulie, M.D., Ph.D.

      11/7/24 4:05:00 PM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PLRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Human Resource Officer Cheung Lily was granted 25,875 shares, increasing direct ownership by 105% to 50,425 units (SEC Form 4)

      4 - PLIANT THERAPEUTICS, INC. (0001746473) (Issuer)

      1/27/25 6:14:06 PM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • General Counsel & Corp. Sec'y Ouimette Mike was granted 35,000 shares, increasing direct ownership by 50% to 105,544 units (SEC Form 4)

      4 - PLIANT THERAPEUTICS, INC. (0001746473) (Issuer)

      1/27/25 6:10:00 PM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Business Officer Hull Hans was granted 40,150 shares, increasing direct ownership by 19% to 251,708 units (SEC Form 4)

      4 - PLIANT THERAPEUTICS, INC. (0001746473) (Issuer)

      1/27/25 6:07:17 PM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care